Company Overview - Hema Medical Holdings Limited is a leading chain ophthalmic medical group in Hong Kong and the Greater Bay Area, focusing on providing professional, high-quality, convenient, and reasonably priced medical services [3] - The company was founded by Dr. Lin Shun Chao and has expanded its operations since establishing its first ophthalmic center in Hong Kong in 2012, now operating 70 medical institutions across Hong Kong and mainland China [3] - Hema Medical has developed the "Eye+" strategy to diversify its medical services beyond ophthalmology, including dental, plastic surgery, family medicine, and oncology [3] Financial Performance - As of December 31, 2024, Hema Medical reported total revenue of 1.772 billion HKD, a year-on-year decrease of 0.56%, and a net profit attributable to shareholders of -125 million HKD, a significant decline of 318.01% [1] - The gross profit margin stood at 27.58%, with a debt-to-asset ratio of 30.52% [1] Market Position and Valuation - Currently, there are no institutional investment ratings for Hema Medical [2] - The company's price-to-earnings (P/E) ratio is -17.25, ranking 73rd in the healthcare equipment and services industry, which has an average P/E ratio of -10.01 [2] - Other companies in the same industry have varying P/E ratios, with some like Giant Medical Holdings at 0.36 and Medical Union Group at 2.32 [2] Upcoming Events - Hema Medical is scheduled to disclose its mid-year report for the fiscal year 2025 on August 26, 2025 [4] - The company anticipates a significant increase in its mid-year earnings, projecting a profit attributable to shareholders between 46 million HKD and 52 million HKD, representing a year-on-year growth of 49% to 69% [4]
希玛医疗（03309.HK）8月20日收盘上涨11.23%，成交1496.43万港元